Table 1.
Baseline characteristics
| Overall response | Responders (N=25) | Non-responders (N=27) | Total (N=52) |
|---|---|---|---|
| Median age, years (IQR) | 57.0 (50.0;66.0) | 63.0 (54.0;67.0) | 59.0 (51.0;67.0) |
| Gender | |||
| Female | 14 (56.0%) | 14 (51.9%) | 28 (53.8%) |
| Male | 11 (44.0%) | 13 (48.1%) | 24 (46.2%) |
| ECOG performance | |||
| 0 | 9 (36.0%) | 6 (22.2%) | 15 (28.8%) |
| 1 | 15 (60.0%) | 21 (77.8%) | 36 (69.2%) |
| 2 | 1 (4.0%) | 0 (0.0%) | 1 (1.9%) |
| First-line regimen | |||
| Bevacizumab + FOLFOX | 24 (96.0%) | 26 (96.3%) | 50 (96.2%) |
| Capecitabine + oxaliplatin | 1 (4.0%) | 1 (3.7%) | 2 (3.8%) |
| Response to first-line treatment | |||
| CR/PR | 19 (76.0%) | 14 (51.9%) | 33 (63.5%) |
| SD/PD | 6 (24.0%) | 13 (48.1%) | 19 (36.5%) |
| Previous anti-angiogenic treatment | |||
| No | 1 (4.0%) | 1 (3.7%) | 2 (3.8%) |
| Yes | 24 (96.0%) | 26 (96.3%) | 50 (96.2%) |
| Previous surgery | |||
| No | 5 (20.0%) | 15 (55.6%) | 20 (38.5%) |
| Yes | 20 (80.0%) | 12 (44.4%) | 32 (61.5%) |
| Primary tumor location | |||
| Ascending colon | 6 (24.0%) | 11 (40.7%) | 17 (32.7%) |
| Descending colon | 1 (4.0%) | 0 (0.0%) | 1 (1.9%) |
| Rectosigmoid colon | 18 (72.0%) | 16 (59.3%) | 34 (65.4%) |
| Metastasis to liver | |||
| No | 8 (32.0%) | 7 (25.9%) | 15 (28.8%) |
| Yes | 17 (68.0%) | 20 (74.1%) | 37 (71.2%) |
| Metastasis to lung | |||
| No | 17 (68.0%) | 14 (51.9%) | 31 (59.6%) |
| Yes | 8 (32.0%) | 13 (48.1%) | 21 (40.4%) |
| Metastasis to bone | |||
| No | 22 (88.0%) | 26 (96.3%) | 48 (92.3%) |
| Yes | 3 (12.0%) | 1 (3.7%) | 4 (7.7%) |
| Baseline median CEA level, ng/mL (IQR) | 3.2 (1.5;5.9) | 12.7 (5.3;129.7) | 5.5 (2.5;40.5) |
| Baseline CEA level | |||
| ≥5 ng/mL | 7 (28.0%) | 20 (74.1%) | 27 (51.9%) |
| <5 ng/mL | 18 (72.0%) | 7 (25.9%) | 25 (48.1%) |
| Mutation of RAS/RAF | |||
| No | 16 (64.0%) | 3 (11.1%) | 19 (36.5%) |
| Yes | 8 (32.0%) | 22 (81.5%) | 30 (57.7%) |
| Non-available | 1 (4.0%) | 2 (7.4%) | 3 (5.8%) |
| Peritoneal seeding | |||
| No | 17 (68.0%) | 16 (59.3%) | 33 (63.5%) |
| Yes | 8 (32.0%) | 11 (40.7%) | 19 (36.5%) |
| MSI status | |||
| MSS | 25 (100%) | 27 (100%) | 52 (100%) |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ECOG, Eastern Cooperative Oncology Group; FOLFOX, fluorouracil plus leucovorin plus oxaliplatin; CEA, carcinoembryonic antigen; MSI, microsatellite instability; MSS, microsatellite stable status; IQR, interquartile range.